Melbourne, Sep 1, 2008 (ABN Newswire) - Mesoblast Limited's (ASX:MSB)(OTC:MBLTY) product has statistically significant higher fusion rates in anterior cervical interbody operations compared to a competitor. We believe the competitor's FY08 cervical fusion sales were cA$325m, but has recently been forced to exit the market.
Mesoblast (MSB.AX): FY08: spinal shock
Long term (12 months): Buy
Target price: A$1.50 (from A$1.30)
Reason: Change of target price
FY08 result - higher-than-expected interest income
MSB posted an NPAT of -A$10.1m for FY08, with a loss below our forecast of -A$10.4m due to higher-than-expected interest income. We believe MSB has sufficient cash (A$14.1m in FY08) to fund its clinical programme for the next one to two years.
A new cervical spine opportunity
Major recent news relates to a new indication for MSB's osteoinductive adult mesenchymal precursor cells (MPCs). MSB recently issued data showing that MSB's MPCs achieved a statistically significant improvement in cervical fusion rates compared to Medtronic's osteoconductive bulking agent (MasterGraft Granules). Given the recent issues with Medtronic's osteoinductive Recombinant Human Bone Morphogenic protein (rhBMP) product (also used in cervical fusion operations) we believe a significant opportunity exists with MSB's MPCs being potentially useful over the medium term in anterior cervical interbody fusion operations.
MSB's MPCs may address the gap in the market for cervical fusion
In July 2008, the US FDA issued a statement that the safety and effectiveness of rhBMP in the cervical spine had not been demonstrated and these products were not approved by FDA for this use. We believe the anterior interbody cervical spine fusion market for BMPs is worth cUS$325m. As a result of the FDA decision, we believe there is currently no synthetic bone graft approved for anterior interbody cervical spine fusions. Medium-term, MSB's MPCs may address this gap in the market.
Buy rating maintained, target price A$1.50
The major changes to our forecasts have been: 1) we believe MSB will get its product to market in FY11 (previously 2HFY10) - hence we believe MSB will not be cash flow positive until FY11; and 2) given the anterior cervical interbody fusion opportunity, we believe initial sales of MSB's cells will be greater, and have updated our forecasts accordingly. As a result of changes to forecasts, our DCF valuation and 12-month target price have increased by 15.4% to A$1.50 per share.
To view the full report, please visit:
http://mesoblast.com.au/investor_analysis.php
Mesoblast (MSB.AX): FY08: spinal shock
Long term (12 months): Buy
Target price: A$1.50 (from A$1.30)
Reason: Change of target price
FY08 result - higher-than-expected interest income
MSB posted an NPAT of -A$10.1m for FY08, with a loss below our forecast of -A$10.4m due to higher-than-expected interest income. We believe MSB has sufficient cash (A$14.1m in FY08) to fund its clinical programme for the next one to two years.
A new cervical spine opportunity
Major recent news relates to a new indication for MSB's osteoinductive adult mesenchymal precursor cells (MPCs). MSB recently issued data showing that MSB's MPCs achieved a statistically significant improvement in cervical fusion rates compared to Medtronic's osteoconductive bulking agent (MasterGraft Granules). Given the recent issues with Medtronic's osteoinductive Recombinant Human Bone Morphogenic protein (rhBMP) product (also used in cervical fusion operations) we believe a significant opportunity exists with MSB's MPCs being potentially useful over the medium term in anterior cervical interbody fusion operations.
MSB's MPCs may address the gap in the market for cervical fusion
In July 2008, the US FDA issued a statement that the safety and effectiveness of rhBMP in the cervical spine had not been demonstrated and these products were not approved by FDA for this use. We believe the anterior interbody cervical spine fusion market for BMPs is worth cUS$325m. As a result of the FDA decision, we believe there is currently no synthetic bone graft approved for anterior interbody cervical spine fusions. Medium-term, MSB's MPCs may address this gap in the market.
Buy rating maintained, target price A$1.50
The major changes to our forecasts have been: 1) we believe MSB will get its product to market in FY11 (previously 2HFY10) - hence we believe MSB will not be cash flow positive until FY11; and 2) given the anterior cervical interbody fusion opportunity, we believe initial sales of MSB's cells will be greater, and have updated our forecasts accordingly. As a result of changes to forecasts, our DCF valuation and 12-month target price have increased by 15.4% to A$1.50 per share.
To view the full report, please visit:
http://mesoblast.com.au/investor_analysis.php
About Mesoblast Limited
Mesoblast Limited (ASX:MSB) (OTC ADR: MBLTY) is the world's leading developer of innovative biological products for the broad field of regenerative medicine.
Mesoblast's commercial strategy is based on its unique proprietary adult mesenchymal precursor cells.
The company's lead products will target cardiovascular conditions, diabetes, inflammatory conditions of lungs and joints, eye diseases, bone marrow cancers, bone fractures, cartilage degeneration and musculoskeletal conditions.
Mesoblast and global biopharmaceutical company Cephalon Inc. have established a strategic alliance to commercialize adult stem cell products for degenerative conditions of the cardiovascular and central nervous systems. The alliance also extends to products for augmenting bone marrow transplantation in cancer patients.
|
||
|
 |
Related Companies |
>>>       Mesoblast Limited |
| |
Related Industry Topics: |
Biotech | Financial General | Health & Pharm General | |
| |
This Page Viewed: (Last 7 Days: 10) (Last 30 Days: 110) (Since Published: 13920) |
Events & Exhibitions
|
Site Search
| ENGLISH All Languages |
AJAX UNION |
|||
|
|||
Companies in the News
ABN Newswire on iPhone/iPad
|
| Download from Apple |
Mobile Video TV
|
||
|
||
